Mutations in the gene encoding the Pit-1 transcriptional activator interfere with the embryologic determination and ultimate functions of anterior pituitary cells that produce growth hormone (GH), prolactin (Prl) and thyroid-stimulating hormone (TSH). Central hypothyroidism is often the presenting feature of combined pituitary hormone deficiency (CPHD), but it is not detected in screening programs that rely upon elevation of TSH. We report a child whose hypothyroidism was recognized clinically at age 6 weeks, and subsequently found to have GH and Prl as well as TSH deficiency. With thyroxine and GH replacement he has reached the 70th percentile for height and has normal intelligence. Molecular analysis of genomic DNA for Pit-1 revealed the presence of compound heterozygous recessive mutations: a nonsense mutation in codon 172 and a novel missense mutation substituting glycine for glutamate at codon 174. This case is the first demonstration of CPHD due to compound heterozygous Pit-1 point mutations, as most reported cases of the CPHD phenotype involve either the dominant negative R271W allele or homozygosity for recessive Pit-1 mutations. Therefore, in cases of CPHD, the possibilities of compound heterozygosity for two different Pit-1 mutations, or homozygosity for mutations in the epigenetic gene, Prop-1, should be considered.

Keywords:
Pit-1, Prop-1, Growth hormone, Thyroid-stimulating hormone, Prolactin, Mutation, Sequencing, Hypothyroidism, Hypopituitarism
1.
Li S, Crenshaw EB III, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG: Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene Pit-1. Nature 1990;347:528–533.
2.
Buckwalter MS, Katz R, Camper SA: Localization of the panhypopituitary dwarf mutation (df) on mouse chromosome 11 in an intersubspecific backcross. Genomics 1991;10:515–526.
3.
Andersen B, Rosenfeld MG: Pit-1 determines cell types during development of the anterior pituitary gland. J Biol Chem 1994;269:29335–29338.
4.
Ingraham HA, Flynn SE, Voss JW, Albert VR, Kapiloff MS, Wilson L, Rosenfeld MG: The POU-specific domain of Pit-1 is essential for sequence-specific, high affinity DNA binding and DNA-dependent Pit-1-Pit-1 interactions. Cell 1990;61:1021–1033.
5.
Parks JS, Pfäffle RW, Brown MR, Abdul-Latif H, Meacham LR: Growth hormone deficiency; in Weintraub BD (ed): Molecular Endocrinology: Basic Concepts and Clinical Correlations. New York, Raven Press, 1995, pp 473–490.
6.
Pfäffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, van der Nat H, van den Brande JL, Rosenfeld MG: Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992;257:1118–1121.
7.
Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE: A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992;257:1115–1118.
8.
Tatsumi KI, Miyai K, Notomi T, Kaibe K, Amino N, Mizuno Y, Kohno H: Cretinism with combined hormone deficiency caused by a mutation in the Pit-1 gene. Nature Genet 1992;1:56–58.
9.
De Zegher F, Pernasetti F, Vanhole C, Devlieger H, Van den Berghe G, Martial JA: The prenatal role of thyroid hormone evidenced by fetomaternal Pit-1 deficiency. J Clin Endocrinol Metab 1995;80:3127–3130.
10.
Liang J, Moye-Rowley S, Maurer RA: In vivo mutational analysis of the DNA binding domain of the tissue-specific transcription factor, Pit-1. J Biol Chem 1995;270:25520–25525.
11.
Ohta K, Nobukuni Y, Mitsubuchi H, Fujimoto S, Matsuo N, Inagaki H, Endo F, Matsuda I: Mutations in the pit-1 gene in children with combined pituitary hormone deficiency. Biochem Biophys Res Commun 1992;189:851–855.
12.
Irie Y, Tatsumi K, Kusuda S, Kawawaki H, Boyages SC, Nose O, Ichiba Y, Katsumata N, Amino N: Screening for PIT 1 abnormality by PCR direct sequencing method. Thyroid 1995;5:207–211.
13.
Sornson MW, Wu W, Dasen JS, Flynn SE, Norman DJ, O’Connell SM, Gukovsky I, Carriere C, Ryan AK, Miller AP, Zuo L, Gleiberman AS, Andersen B, Beamer WG, Rosenfeld MG: Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 1996;384:327–333.
14.
Cohen LE, Wondisford FE, Radovick S: A novel mutation in the phosphorylation consensus sequence of the Pit-1 gene in a patient with dysregulation of prolactin and thyrotropin secretion. Proc 76th Meet Endocr Soci, Anaheim, 1994.
15.
Cohen LE, Wondisford FE, Salvatoni A, Maghnie M, Brucker-Davis F, Weintraub BD, Radovick S: A hot spot in the Pit-1 gene responsible for combined pituitary hormone deficiency: Clinical and molecular correlates. J Clin Endocrinol Metab 1995;80:679–684.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.